DNMT1 and cancer: As a result, multiple epigenetic modifying drugs have been approved for cancer treatment, including the HDAC inhibitors vorinostat, romidepsin, belinostat, panobinostat, and chidamide, and the DNMT inhibitors azacytidine and decitabine [20].